Abstract:ConspectusClustered, regularly interspaced, short palindromic repeat (CRISPR)/associated protein 9 (CRISPR/Cas9) is emerging as a powerful genome-editing tool, enabling precise and targeted modifications of virtually any genomic sequence in living cells. These technologies have potential therapeutic applications for cancers, metabolic diseases, and genetic disorders. However, several major challenges hinder the full realization of their potential. Specifically, CRISPR-Cas9 gene editors, whether delivered as plasmid DNA, mRNA/sgRNA, or ribonucleoprotein (RNP), exhibit poor membrane permeability, restricting their access to the intracellular genome, where the editing occurs. Additionally, these editors lack tissue or organ specificity, raising concerns about off-target editing at the tissue level that causes unwanted genotoxicity. Though a range of delivery carriers has been developed to deliver Cas9 editors, their effectiveness is often limited by a number of barriers at both the extracellular and intracellular levels. Moreover, the prolonged activity of Cas9 increases the risk of off-target editing at the genomic level. Therefore, it is crucial to develop efficient delivery vectors, along with molecular switches to safely regulate Cas9 activity.In this Account, we summarize our recent achievements in developing different types of materials that can efficiently deliver the plasmid DNA encoding Cas9 protein and single-guide RNA (sgRNA), or Cas9 RNP into cells to highlight the design considerations of carriers for safe and efficient delivery in vitro and in vivo. After elucidating the chemical and physical factors that are responsible for encapsulating and delivering these biomacromolecules, we further elucidate how we design the biodegradable polymeric carriers using dynamic disulfide chemistry, emphasize their safe and efficient delivery features for genome-editing biomacromolecules, and also introduce the integration of the intracellular delivery of genome-editing biomacromolecules with microneedle-based transdermal delivery to promote therapeutic genome editing for inflammatory skin disorders. Finally, we review how we exploit optical, chemical, and genetic switches to control the Cas9 activity in conjunction with targeted delivery to address the spatiotemporal specificity of gene editing in vivo and demonstrate their precision therapy against cancer and colitis treatment as proof-of-concept examples. In the final part, we will summarize the progress we have made and propose the future directions that may impact the field based on our own research outcomes.

Optimized Plasmid Construction Strategy for Cas9

SgRNA Engineering for Improved Genome Editing and Expanded Functional Assays.

[Optimization of CRISPR/Cas9-based multiplex base editing in Corynebacterium glutamicum].

Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.

Efficient expression of multiple guide RNAs for CRISPR/Cas genome editing

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

Efficient genome engineering in eukaryotes using Cas9 from Streptococcus thermophilus.

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Improving the efficiency of CRISPR-Cas12a-based genome editing with site-specific covalent Cas12a-crRNA conjugates

Improving the Efficiency of Precise Genome Editing with Site-Specific Cas9-oligonucleotide Conjugates

Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies

Convergent Arrangement of sgRNA and Cas9 in CRISPRsome for Transcellular Trafficking

Chemical Modification and Transformation Strategies of Guide RNAs in CRISPR‐Cas9 Gene Editing Systems

Construction of an Easy-to-use CRISPR-Cas9 System by Patching a Newly Designed EXIT Circuit

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing

Genome editing with natural and engineered CjCas9 orthologs

CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell Embryos

Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency

Development of Delivery Strategies for CRISPR‐Cas9 Genome Editing

Rationally designed Campylobacter jejuni Cas9 enables efficient gene activation and base editing